IP Library › Granted Patent US 6,890,906
Granted Patent B2
US 6,890,906 · App. 10/299,478 · Granted May 10, 2005

Method for controlling angiogenesis in animals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,890,906
App. No.
10/299,478
Granted
May 10, 2005
Kind
B2
Abstract

Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.

Claims (27)

1. A method for controlling angiogenesis in an organism, said method comprising administering to said organism a therapeutically effective amount of a compound which binds to a galectin, said compound comprising a polymeric backbone which is a partially demethoxylated polygalacturonic acid interrupted with rhamnose residues.

2. The method of claim 1 , wherein said galectin is present on the cell surface of a tissue of said organism.

3. The method of claim 1 , wherein said compound binds to galectin-1 or galectin-3.

4. The method of claim 1 , wherein said compound comprises a polymeric backbone having a side chains dependent from said backbone, said side chains comprising one or more sugars and being terminated by a galactose or arabinose unit.

5. The method of claim 1 , wherein said compound comprises a modified pectin.

6. The method of claim 5 , wherein said modified pectin comprises a pH modified pectin.

7. The method of claim 5 , wherein said modified pectin comprises an enzymatically modified pectin.

8. The method of claim 5 , wherein said modified pectin comprises a thermally modified pectin.

9. The method of claim 5 , wherein said modified pectin comprises a modified citrus pectin.

10. The method of claim 5 , wherein said modified pectin has a molecular weight in the range of 1-50 kilodalton.

11. The method of claim 5 , wherein said modified pectin has a molecular weight in the range of 25-40 kilodalton.

12. The method of claim 5 , wherein the modified pectin has a molecular weight of approximately 25 kilodalton.

13. The method of claim 5 , wherein said modified pectin has a molecular weight of approximately 10 kilodalton.

14. The method of claim 5 , wherein said modified pectin has a molecular weight in the range of 15-60 kilodalton.

15. The method of claim 1 , wherein said compound has a molecular weight of at least 300 dalton.

16. The method of claim 1 , wherein administering said compound to said organism comprises injecting said compound into said organism.

17. The method of claim 1 , wherein administering said compound to said organism comprises topically applying said compound to said organism.

18. The method of claim 1 , wherein administering said compound to said organism comprises administering said compound transdermally.

19. The method of claim 1 , wherein administering said compound to said organism comprises orally administering said compound.

20. A method for the therapeutic treatment of a disease in an animal, the progress of which disease is dependent upon neovascularization in the tissues of said animal, said method comprising: administering to said animal a therapeutically effective amount of a compound which binds to a galectin, said compound comprising a polymeric backbone which is a partially demethoxylated polygalacturonic acid interrupted with rhamnose residues; whereby said compound decreases the rate of angiogenesis and neovascularization in said tissues.

21. The method of claim 20 , wherein said compound binds to galectin-1 or galectin-3.

22. The method of claim 20 , wherein said compound further comprises a side chains dependent from said backbone, said side chains comprising one or more sugars and being terminated by a galactose or arabinose unit.

23. The method of claim 20 , wherein said compound comprises a modified pectin.

24. A method for controlling angiogenesis in an organism, said method comprising:

administering to said organism a therapeutically effective amount of modified pectin.

25. The method of claim 24 , wherein the modified pectin is thermally modified pectin.

26. The method of claim 24 , wherein the modified pectin is pH-modified pectin.